Neumora Therapeutics, Inc.
NMRANasdaqCIK 1885522HealthcareFiscal year ends Dec 31
Reports and events: 56 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-3016:05 ET | 8-K | 3.01 Delisting notice | 0001193125-26-441634 |
| 2026-08-1407:23 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-350370 |
| 2026-08-1407:13 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-350349 |
| 2026-07-2707:07 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-316819 |
| 2026-06-1508:15 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 2.05 Exit or disposal costs; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-270328 |
| 2026-05-2916:05 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-248244 |
| 2026-05-0716:01 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-211825 |
| 2026-05-0707:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210310 |
| 2026-04-1716:04 ET | DEF 14A | Proxy statementPeriod 2026-05-27 | 0001193125-26-161489 |
| 2026-04-0116:10 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001012975-26-000294 |
| 2026-03-3007:07 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-130388 |
| 2026-03-3006:58 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-130372 |
| 2026-02-1107:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-045526 |
| 2026-01-1207:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-009727 |
| 2026-01-0506:44 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-001472 |
| 2025-11-2116:05 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-291352 |
| 2025-11-0616:02 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-269446 |
| 2025-11-0607:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-268046 |
| 2025-10-2919:07 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001012975-25-000675 |
| 2025-10-2707:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-250677 |
| 2025-10-2706:34 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-250656 |
| 2025-08-0616:31 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104138 |
| 2025-08-0616:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-103997 |
| 2025-05-3017:21 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-132307 |
| 2025-05-1616:26 ET | 8-K | 3.01 Delisting notice | 0001193125-25-121714 |
| 2025-05-1216:33 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-069311 |
| 2025-05-1216:04 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-069147 |
| 2025-04-2916:03 ET | DEF 14A | Proxy statementPeriod 2025-05-28 | 0000950170-25-060084 |
| 2025-04-1116:34 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0000950170-25-053303 |
| 2025-03-0307:32 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-030401 |
| 2025-03-0307:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-030396 |
| 2025-02-2116:01 ET | 8-K/A | 5.02 Departure or appointment of officers or directors | 0001193125-25-031974 |
| 2025-02-1316:51 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-026156 |
| 2025-01-1308:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-004999 |
| 2025-01-0207:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-000084 |
| 2024-11-2217:33 ET | SC 13D/A | Ownership report, active investor, amended | 0001072613-24-000899 |
| 2024-11-1216:15 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-125437 |
| 2024-11-1207:17 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-124563 |
| 2024-08-0616:02 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-091737 |
| 2024-08-0607:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-091205 |
| 2024-06-1416:01 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-161572 |
| 2024-05-0716:01 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-054448 |
| 2024-05-0707:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-053933 |
| 2024-04-2516:05 ET | DEF 14A | Proxy statementPeriod 2024-06-13 | 0000950170-24-048287 |
| 2024-04-1506:46 ET | 8-K | 8.01 Other events | 0001193125-24-095472 |
| 2024-03-0716:05 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-027927 |
| 2024-03-0707:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-24-061473 |
| 2024-01-0808:32 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-003968 |
| 2023-12-1517:06 ET | SC 13D/A | Ownership report, active investor, amended | 0001072613-23-000627 |
| 2023-11-2816:21 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-284303 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 16:11 ET. Listed shows no prices and gives no investment advice.